The NCT00923312 trial used CV9201, an mRNA-based vaccine with free and protamine-complexed full-length mRNAs that encodes for five NSCLC-related antigens: New York esophageal squamous cell carcinoma-1 (NY-ESO-1), melanoma antigen family C1 and C2, survivin, and trophoblast glycoprotein (5T4). The gene discussed is MAGEC1; the disease is non-small cell lung carcinoma.